200 related articles for article (PubMed ID: 9536262)
1. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA.
Li HF; Yang YH; Shi YJ; Wang YQ; Zhu P
Chin Med J (Engl); 2004 Sep; 117(9):1348-52. PubMed ID: 15377427
[TBL] [Abstract][Full Text] [Related]
4. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
6. Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells.
Finke S; Trojaneck B; Möller P; Schadendorf D; Neubauer A; Huhn D; Schmidt-Wolf IG
Cancer Gene Ther; 1997; 4(4):260-8. PubMed ID: 9253512
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
8. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
9. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
10. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
Marin V; Kakuda H; Dander E; Imai C; Campana D; Biondi A; D'Amico G
Exp Hematol; 2007 Sep; 35(9):1388-97. PubMed ID: 17656004
[TBL] [Abstract][Full Text] [Related]
12. Towards endothelial-cell-directed cancer immunotherapy: in vitro expression of human recombinant cytokine genes by human and mouse primary endothelial cells.
Ojeifo JO; Su N; Ryan US; Verma UN; Mazumder A; Zwiebel JA
Cytokines Mol Ther; 1996 Jun; 2(2):89-101. PubMed ID: 9384693
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-7 gene transfection into ovarian carcinoma cell line SKOV3 in vitro and in vivo.
Xie X; Ye DF; Chen HZ; Lu WG; Fu YF; Cheng B; Zhu H
Gynecol Oncol; 2004 Feb; 92(2):578-85. PubMed ID: 14766250
[TBL] [Abstract][Full Text] [Related]
15. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
16. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation.
Zoll B; Lefterova P; Ebert O; Huhn D; Von Ruecker A; Schmidt-Wolf IG
Cytokine; 2000 Sep; 12(9):1385-90. PubMed ID: 10975999
[TBL] [Abstract][Full Text] [Related]
18. Increase in proliferation rate and normalization of TNF-alpha secretion by blockage of gene transfer-induced apoptosis in lymphocytes using low-dose cyclosporine A.
Röpke G; Ebert O; Märten A; Lefterova P; Micka B; Buttgereit P; Niemitz S; Trojaneck B; Schmidt-Wolf G; Rücker AV; Huhn D; Wittig B; Schmidt-Wolf IG
Cancer Gene Ther; 2000 Nov; 7(11):1411-3. PubMed ID: 11129282
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
[TBL] [Abstract][Full Text] [Related]
20. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
Yoshimura K; Hazama S; Iizuka N; Yoshino S; Yamamoto K; Muraguchi M; Ohmoto Y; Noma T; Oka M
Cancer Gene Ther; 2001 Jan; 8(1):9-16. PubMed ID: 11219497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
